Epixa 60 Tablet contains Etoricoxib 60 mg, a selective cyclooxygenase-2 (COX-2) inhibitor used primarily for the management of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. By selectively inhibiting the COX-2 enzyme, Epixa 60 reduces the synthesis of prostaglandins responsible for inflammation and pain, while sparing COX-1, thereby minimizing gastrointestinal side effects commonly associated with non-selective NSAIDs. It is indicated for short-term and long-term treatment of chronic musculoskeletal conditions and acute pain episodes. The recommended dosage should be individualized based on the patient’s clinical condition and response to therapy, with careful consideration of cardiovascular and gastrointestinal risk factors. Epixa 60 is contraindicated in patients with known hypersensitivity to Etoricoxib or other NSAIDs, active peptic ulcer disease, severe hepatic or renal impairment, and established cardiovascular disease. Common adverse effects may include headache, dizziness, hypertension, and gastrointestinal discomfort. Patients should be monitored regularly for signs of cardiovascular events, renal function changes, and gastrointestinal bleeding. Epixa 60 should be used with caution in patients with risk factors for cardiovascular disease and should be avoided during the third trimester of pregnancy. It is essential to adhere to prescribed dosages to optimize therapeutic outcomes and minimize potential risks.